Head and Neck Squamous Cell Carcinoma (HNSCC) Not Yet Recruiting Phase 1 / 2 Trials for Nivolumab (DB09035)

Also known as: Head and Neck Squamous Cell Carcinoma

IndicationStatusPhase
DBCOND0043665 (Head and Neck Squamous Cell Carcinoma (HNSCC))Not Yet Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03655444Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based ChemotherapyTreatment
NCT03169764QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyTreatment